An anti-tumor abundant immune-infiltrate, indicated by high CD8+T-lymphocytes and low T-regulatory cells, is a strong predictor of good response to chemotherapy in breast cancer patients [52, 53], suggesting that part of the anti-tumor effects of anthracyclines is mediated by the engagement of the host immune system. The gene discussed is CD8A; the disease is breast carcinoma.